Insider buying last 90 days
No open-market insider purchases were filed for RIGL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RIGL insider filing, plotted on the chart in Gekko.Open RIGL in Gekko
NASDAQ: RIGL
Rigel Pharmaceuticals (RIGL) Stock Analysis & Forecast
Oct 12 close
$48.81−0.27 (−0.6%)
Gekko Brief
Oct 12 closeRigel Pharmaceuticals closed at $48.81 on 12 October 2026, -0.6% on the day. The price sits above both the 50-day ($45.72) and 200-day ($36.70) moving averages, inside a 52-week range of $24.95 to $52.24. The GekkoIndex reads 52.5, in the Neutral zone, down 2 points over five sessions. Gekko Fair Value is $52.49, so the price is 7% below it.
The next earnings report is due on 3 November 2026, 22 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 18.3% across the report. Seasonally, the next 20 trading days from this point averaged -6.3% over the last 5 years, rising in 1 of them.
4 firms rate the stock: 2 buy, 2 hold and 0 sell, with a consensus target of $63.00. A typical daily move is about 3.8%, and a typical 20-day move about 15.1%. On the swing-trade checklist, 2 items read supportive and 2 read as a headwind (earnings risk, seasonality).
A plain summary of the figures as of the Oct 12, 2026 close.
Rigel Pharmaceuticals price vs fair value
Close $48.81200-day averageGekko Fair Value $52.49
Rigel Pharmaceuticals quick facts
- Market cap
- $903.1M
- P/E ratio
- 2.9
- Forward P/E
- 9.3
- EPS, TTM
- $16.88
- Revenue, TTM
- $276.8M
- Profit margin
- 116.3%
- Dividend yield
- —
- Beta
- 1.19
- Volume
- 162,515 avg 251,380
- 1-year return
- +71.9%
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±15.1%
- 50-day average
- $45.72
- 200-day average
- $36.70
- Next earnings
- Nov 3 after close
- Shares outstanding
- 18.50M
Rigel Pharmaceuticals swing-trade checklist
Rigel Pharmaceuticals scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $48.81 is above the 50-day ($45.72) and 200-day ($36.70) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
52.5, Neutral
Reading 52.5 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
7.0% below
Price is 7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 22 days
Reports on Nov 3, 2026, 22 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−6.3% on average
From this point in the calendar, the next 20 trading days averaged −6.3% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Rigel Pharmaceuticals stock chart and price history
Rigel Pharmaceuticals closed at $48.81 on Oct 12, 2026, +71.9% over the past year, inside a 52-week range of $24.95 to $52.24.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.3%
- 3 months
- +18.6%
- 6 months
- +62.9%
- 1 year
- +71.9%
The full RIGL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RIGL in Gekko
Follow Rigel Pharmaceuticals through every session
Put RIGL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RIGL in GekkoFree for 7 days. No credit card required.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals focuses on treatments for blood disorders and cancer, selling its medicines to patients in the United States. Its portfolio includes Tavalisse, taken by mouth to treat chronic immune thrombocytopenia in adults, Rezlidha for adults with relapsed or refractory acute myeloid leukemia carrying a specific IDH1 mutation, and Gavreto, a daily oral treatment for certain lung and thyroid cancers linked to RET fusion mutations. The company is also working on R289, an early-stage compound aimed at blood cancers as well as autoimmune and inflammatory conditions, including a lower-risk form of myelodysplastic syndrome.
Beyond its marketed products, Rigel pursues joint research efforts rather than working alone on every program. It partners with MD Anderson Cancer Center to study olutasidenib in AML and related blood cancers tied to IDH1 mutations, and takes part in the CONNECT network's trial testing olutasidenib alongside temozolomide for high-grade glioma patients with the same mutation.
The company traces back to its incorporation in 1996 and operates out of South San Francisco, California. Its shares are listed on the NASDAQ under the ticker RIGL.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- rigel.com
Rigel Pharmaceuticals GekkoIndex: the smart money zone
Rigel Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.5, in the Neutral zone, down 2 points over five sessions.
52.5Neutral
Down 2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 58 | −0.4% | +11.4% |
| Accumulation | 212 | +1.8% | +7.9% |
| Neutral (current zone) | 347 | +1.3% | +7.8% |
| Distribution | 51 | +2.8% | −4.1% |
| Selling | 14 | +6.2% | −2.0% |
Average RIGL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the RIGL price, zone by zone.Track RIGL in Gekko
Is Rigel Pharmaceuticals stock overvalued? Gekko Fair Value
Rigel Pharmaceuticals trades 7.0% below Gekko Fair Value of $52.49, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Rigel Pharmaceuticals shares are worth, recalculated every trading day.
$52.49
Gekko Fair Value, Oct 10, 2026
7.0% Undervalued
At the end of Aug 2026 the price was 16.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open RIGL in Gekko
Rigel Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Rigel Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RIGL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RIGL, plotted on the chart in Gekko.Open RIGL in Gekko
Buybacks
Rigel Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $3.74M
- As a share of market cap
- 0.41%
From company filings.
Rigel Pharmaceuticals earnings: next date and track record
Rigel Pharmaceuticals reports on Nov 3, 2026, after the close (22 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected after the close, 22 days away
- EPS estimate
- $0.92
- Revenue estimate
- $80.10M
5 of 8reports beat the EPS estimate
±18.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Rigel presented Q2 2026 results highlighting product sales growth and strategic progress. U.S. net product sales were $67.0M (up 14% YoY) driven by record TAVALISSE sales of $47.4M (up 18%) and REZLIDHIA sales of $8.9M (up 27%); GAVRETO showed a modest decline. Total Q2 revenues were $78.7M, with net income of $17.3M (down from $59.6M YoY, which included a $40M non-cash revenue in prior-year quarter). Rigel completed the exclusive global license of vepdegestrant (VEPPANU), expects commercial availability mid-August, and will prioritize its launch. The company advanced R289 dose expansion with a year-end readout planned and continues collaborations (MD Anderson and others). Management maintained product sales guidance for existing products ($255M-$265M) and increased contract revenue expectations to approximately $30M; no near-term sales guidance was given for VEPPANU. The call emphasized a strategy to grow the commercial portfolio, expand via in-licensing/acquisitions, advance clinical programs, and maintain financial discipline.
- Guidance
- Maintained product sales guidance of $255 million - $265 million for TAVALISSE, GAVRETO, and REZLIDHIA. Increased contract revenue expectation to approximately $30 million (up from prior $20M-$30M range). No guidance issued yet for VEPPANU; company will consider issuing guidance after initial launch traction (Q3/Q4 results).
- Risks flagged
- Standard forward-looking caution noted (SEC filings). Mentioned headwinds include increased R&D and personnel costs, higher cost of product sales, the absence of near-term guidance for newly in-licensed VEPPANU (launch execution risk), and the impact of prior-year non-cash collaboration revenue on year-over-year comparability. Implicit risks: regulatory/market access timing, competition in breast cancer oral SERD space, and dependency on successful commercialization and adoption of VEPPANU.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.88 est $0.91 | $78.70M est $55.27M | +8.1% |
| May 5, 2026 | $0.44 est $0.87 | $58.82M est $62.40M | −9.7% |
| Mar 3, 2026 | $1.12 est $1.20 | $69.80M est $68.70M | −14.4% |
| Nov 4, 2025 | $1.46 est $0.01 | $69.46M est $68.42M | +23.5% |
| Aug 5, 2025 | $3.28 est −$0.03 | $101.7M est $62.31M | +31.5% |
| May 6, 2025 | $0.63 est $0.09 | $53.33M est $48.32M | −3.3% |
| Mar 4, 2025 | $0.80 est $0.58 | $57.60M est $57.59M | −9.3% |
| Nov 7, 2024 | $0.70 est $0.06 | $55.31M est $47.42M | +46.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Rigel Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Rigel Pharmaceuticals is $63.00, +29.1% from the last close, from 4 firms rating the stock in the last 90 days.
$63.00consensus 12-month target, +29.1% from the last close
Now $48.81Avg $63.00
Low $43High $85
Each firm’s latest rating in the last 90 days: 4 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | H.C. Wainwright | $85 | +74.1% |
| Sep 8 | H.C. Wainwright | $85 | +74.1% |
| Aug 17 | Piper Sandler | $49 | +0.4% |
| Aug 14 | H.C. Wainwright | $85 | +74.1% |
| Aug 6 | Citi | $83 | +70.0% |
+7.8%average 20-day move after past Neutral readings
−6.3%average move over the next 20 trading days in the last 5 years
±3.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Rigel Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Rigel Pharmaceuticals averaged −6.3% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −6.6% | 1 of 5 |
| Next 10 trading days | −12.5% | 1 of 5 |
| Next 15 trading days | −9.8% | 2 of 5 |
| Next 20 trading days | −6.3% | 1 of 5 |
| Next 30 trading days | +12.7% | 2 of 5 |
For scale, RIGL’s typical 20-trading-day move in either direction is about 15.1%.
Rigel Pharmaceuticals market cap and key statistics
Rigel Pharmaceuticals’s market cap is $903.1M, with a P/E ratio of 2.9 and revenue of $276.8M over the last twelve months.
Valuation
- Market cap
- $903.1M
- P/E ratio
- 2.9
- Forward P/E
- 9.3
- EPS, TTM
- $16.88
- Gekko Fair Value
- $52.49
Trading
- Volume
- 162,515
- Avg volume, 20 days
- 251,380
- 52-week high
- $52.24
- 52-week low
- $24.95
- Shares outstanding
- 18.50M
Financials
- Revenue, TTM
- $276.8M
- Profit margin
- 116.3%
- Return on equity
- 126.9%
- Quarterly earnings growth, YoY
- −73.2%
Risk and income
- Beta
- 1.19
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±15.1%
Rigel Pharmaceuticals stock news this week
Coverage of Rigel Pharmaceuticals this week reads negative: 1 positive, 1 neutral and 3 negative headlines.
- H.C. Wainwright Sticks to Their Buy Rating for Rigel (RIGL)The Globe and Mail, Oct 7
- Trading Systems Reacting to (RIGL) VolatilityStock Traders Daily, Oct 6
- Rigel Pharmaceuticals Inc. Advanced Charts | RI2Barron's, Oct 5
- Rigel Pharmaceuticals Inc. Research & Ratings | RI2Barron's, Oct 5
- Rigel Pharmaceuticals Inc. Company & People | RI2Barron's, Oct 5
Rigel Pharmaceuticals peers
Rigel Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Rigel Pharmaceuticals stock FAQ
What is Rigel Pharmaceuticals’s market cap?
Rigel Pharmaceuticals’s market cap is $903.1M at the Oct 12, 2026 close of $48.81, with 18.50M shares outstanding. The shares trade on a P/E ratio of 2.9.
What is the Rigel Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Rigel Pharmaceuticals is $63.00, +29.1% from the last close. Of the 4 firms that rated the stock in the last 90 days, 2 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Rigel Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Rigel Pharmaceuticals is undervalued: the Oct 12, 2026 close of $48.81 is 7.0% below Gekko Fair Value of $52.49. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Rigel Pharmaceuticals report earnings next?
Rigel Pharmaceuticals is expected to report on Nov 3, 2026, after the market closes (22 days away). Analysts expect earnings of $0.92 per share on revenue of $80.10M. Rigel Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 18.3% on average across the report.
What is Rigel Pharmaceuticals’s 52-week high and low?
Rigel Pharmaceuticals’s 52-week high is $52.24 and its 52-week low is $24.95; it closed at $48.81 on Oct 12, 2026, +71.9% over the past year.
Is Rigel Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and fair value), 1 as mixed (gekkoindex) and 2 as headwinds (earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Rigel Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.